Abstract
HER2-deregulated non–small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective drugs. Recent evidence suggests that osimertinib could be effective in HER2-amplified or mutated lung cancer as a single agent or in combination. Clin Cancer Res; 24(11); 2470–2. ©2018 AACR.
See related article by Liu et al., p. 2594
- Received February 7, 2018.
- Revision received February 13, 2018.
- Accepted February 27, 2018.
- Published first March 1, 2018.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
June 2018
Volume 24, Issue 11
Volume 24, Issue 11
HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Jump to section
Advertisement